Adjuvant ipilimumab in high-risk Uveal melanoma

Eric Fountain, Roland L. Bassett, Suzanne Cain, Liberty Posada, Dan S Gombos, Patrick Hwu, Agop Bedikian, Sapna Pradyuman Patel

Research output: Contribution to journalArticle

Abstract

Uveal melanoma is a common intraocular malignant tumor that is uniformly fatal once metastatic. No effective adjuvant therapy currently exists to reduce the risk of distant metastasis after definitive treatment of the primary lesion. Immunotherapy has been used effectively in the adjuvant setting in locally advanced cutaneous melanoma. We performed a Phase I/II clinical trial of adjuvant ipilimumab in high-risk primary uveal melanoma with distant metastasis-free survival (DMFS) as the primary objective. A total of 10 patients with genomically high-risk disease were treated: three at a dose of 3 mg/kg and seven at 10 mg/kg. Two of the seven patients at the higher dose had to discontinue therapy secondary to grade 3 toxicity. At 36 months follow-up, 80% of patients had no evidence of distant disease (95% CI, 58.7–100). With recent advancements in CTLA-4 inhibition, PD-1 inhibition, and combined checkpoint blockade, immunotherapy is a promising avenue of treatment in uveal melanoma. Further clinical trials are needed to elucidate the role of immunotherapy in the adjuvant setting.

Original languageEnglish (US)
Article number152
JournalCancers
Volume11
Issue number2
DOIs
StatePublished - Jan 1 2019

Fingerprint

Immunotherapy
Neoplasm Metastasis
Phase II Clinical Trials
Clinical Trials, Phase I
Therapeutics
Melanoma
Clinical Trials
Skin
Survival
ipilimumab
Uveal melanoma
Neoplasms

Keywords

  • Adjuvant
  • Class 2
  • Clinical trial
  • High-risk
  • Ipilimumab
  • Uveal melanoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adjuvant ipilimumab in high-risk Uveal melanoma. / Fountain, Eric; Bassett, Roland L.; Cain, Suzanne; Posada, Liberty; Gombos, Dan S; Hwu, Patrick; Bedikian, Agop; Patel, Sapna Pradyuman.

In: Cancers, Vol. 11, No. 2, 152, 01.01.2019.

Research output: Contribution to journalArticle

Fountain, E, Bassett, RL, Cain, S, Posada, L, Gombos, DS, Hwu, P, Bedikian, A & Patel, SP 2019, 'Adjuvant ipilimumab in high-risk Uveal melanoma' Cancers, vol. 11, no. 2, 152. https://doi.org/10.3390/cancers11020152
Fountain E, Bassett RL, Cain S, Posada L, Gombos DS, Hwu P et al. Adjuvant ipilimumab in high-risk Uveal melanoma. Cancers. 2019 Jan 1;11(2). 152. https://doi.org/10.3390/cancers11020152
Fountain, Eric ; Bassett, Roland L. ; Cain, Suzanne ; Posada, Liberty ; Gombos, Dan S ; Hwu, Patrick ; Bedikian, Agop ; Patel, Sapna Pradyuman. / Adjuvant ipilimumab in high-risk Uveal melanoma. In: Cancers. 2019 ; Vol. 11, No. 2.
@article{05b2c95e6a864936904b3f3504b91346,
title = "Adjuvant ipilimumab in high-risk Uveal melanoma",
abstract = "Uveal melanoma is a common intraocular malignant tumor that is uniformly fatal once metastatic. No effective adjuvant therapy currently exists to reduce the risk of distant metastasis after definitive treatment of the primary lesion. Immunotherapy has been used effectively in the adjuvant setting in locally advanced cutaneous melanoma. We performed a Phase I/II clinical trial of adjuvant ipilimumab in high-risk primary uveal melanoma with distant metastasis-free survival (DMFS) as the primary objective. A total of 10 patients with genomically high-risk disease were treated: three at a dose of 3 mg/kg and seven at 10 mg/kg. Two of the seven patients at the higher dose had to discontinue therapy secondary to grade 3 toxicity. At 36 months follow-up, 80{\%} of patients had no evidence of distant disease (95{\%} CI, 58.7–100). With recent advancements in CTLA-4 inhibition, PD-1 inhibition, and combined checkpoint blockade, immunotherapy is a promising avenue of treatment in uveal melanoma. Further clinical trials are needed to elucidate the role of immunotherapy in the adjuvant setting.",
keywords = "Adjuvant, Class 2, Clinical trial, High-risk, Ipilimumab, Uveal melanoma",
author = "Eric Fountain and Bassett, {Roland L.} and Suzanne Cain and Liberty Posada and Gombos, {Dan S} and Patrick Hwu and Agop Bedikian and Patel, {Sapna Pradyuman}",
year = "2019",
month = "1",
day = "1",
doi = "10.3390/cancers11020152",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Adjuvant ipilimumab in high-risk Uveal melanoma

AU - Fountain, Eric

AU - Bassett, Roland L.

AU - Cain, Suzanne

AU - Posada, Liberty

AU - Gombos, Dan S

AU - Hwu, Patrick

AU - Bedikian, Agop

AU - Patel, Sapna Pradyuman

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Uveal melanoma is a common intraocular malignant tumor that is uniformly fatal once metastatic. No effective adjuvant therapy currently exists to reduce the risk of distant metastasis after definitive treatment of the primary lesion. Immunotherapy has been used effectively in the adjuvant setting in locally advanced cutaneous melanoma. We performed a Phase I/II clinical trial of adjuvant ipilimumab in high-risk primary uveal melanoma with distant metastasis-free survival (DMFS) as the primary objective. A total of 10 patients with genomically high-risk disease were treated: three at a dose of 3 mg/kg and seven at 10 mg/kg. Two of the seven patients at the higher dose had to discontinue therapy secondary to grade 3 toxicity. At 36 months follow-up, 80% of patients had no evidence of distant disease (95% CI, 58.7–100). With recent advancements in CTLA-4 inhibition, PD-1 inhibition, and combined checkpoint blockade, immunotherapy is a promising avenue of treatment in uveal melanoma. Further clinical trials are needed to elucidate the role of immunotherapy in the adjuvant setting.

AB - Uveal melanoma is a common intraocular malignant tumor that is uniformly fatal once metastatic. No effective adjuvant therapy currently exists to reduce the risk of distant metastasis after definitive treatment of the primary lesion. Immunotherapy has been used effectively in the adjuvant setting in locally advanced cutaneous melanoma. We performed a Phase I/II clinical trial of adjuvant ipilimumab in high-risk primary uveal melanoma with distant metastasis-free survival (DMFS) as the primary objective. A total of 10 patients with genomically high-risk disease were treated: three at a dose of 3 mg/kg and seven at 10 mg/kg. Two of the seven patients at the higher dose had to discontinue therapy secondary to grade 3 toxicity. At 36 months follow-up, 80% of patients had no evidence of distant disease (95% CI, 58.7–100). With recent advancements in CTLA-4 inhibition, PD-1 inhibition, and combined checkpoint blockade, immunotherapy is a promising avenue of treatment in uveal melanoma. Further clinical trials are needed to elucidate the role of immunotherapy in the adjuvant setting.

KW - Adjuvant

KW - Class 2

KW - Clinical trial

KW - High-risk

KW - Ipilimumab

KW - Uveal melanoma

UR - http://www.scopus.com/inward/record.url?scp=85062343304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062343304&partnerID=8YFLogxK

U2 - 10.3390/cancers11020152

DO - 10.3390/cancers11020152

M3 - Article

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 2

M1 - 152

ER -